UK-HIFU

UK HIFU is the United Kingdom-based commercial and clinical organization representing Sonablate Corp, a global leader in high-intensity focused ultrasound (HIFU) technology. The company specializes in the non-invasive treatment of prostate cancer using the Sonablate device, which employs focused ultrasound energy to ablate cancerous tissue with high precision. UK HIFU operates as a hub for sales, physician training, and technical support across the UK and Europe, facilitating the adoption of focal therapy as a middle-ground alternative between active surveillance and radical surgery. The organization is closely integrated with leading academic and clinical centers, including the UK HIFU Unit at Oxford University Hospitals and University College London, where it supports extensive research and maintains the HEAT (HIFU Evaluation and Assessment of Treatment) registry. Its primary mission is to provide patients with localized or recurrent prostate cancer a treatment option that effectively controls cancer while significantly reducing the risk of life-altering side effects such as urinary incontinence and erectile dysfunction.